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Abstract 
Gillespie syndrome (GS) is characterized by bilateral iris hypoplasia, congenital 
hypotonia, non-progressive ataxia and progressive cerebellar atrophy.  Trio-based 
exome sequencing identified de novo mutations in ITPR1 in three unrelated individuals 
with GS recruited to the Deciphering Developmental Disorders study.  Whole exome or 
targeted sequence analysis identified plausible disease-causing ITPR1 mutations in 
10/10 additional GS individuals.  These ultra-rare protein-altering variants affected only 
three residues in ITPR1; Glu2094 missense (1 de novo, 1 co-segregating), Gly2539 
missense (5 de novo, 1 inheritance uncertain) and Lys2596 in-frame deletion (4 de 
novo).  No clinical or radiological differences were evident between individuals with 
different mutations. ITPR1 encodes an inositol 1, 4, 5-triphosphate-responsive calcium 
channel.  The homo-tetrameric structure has been solved using cryoelectron 
microscopy.  Using estimations of the degree of structural change induced by known 
recessive and dominant negative mutations in other disease-associated multimeric 
channels we developed a generalizable computational approach to indicate the likely 
mutational mechanism.  This analysis supports a dominant negative mechanism for 
GS variants in ITPR1.  In GS-derived lymphoblastoid cell lines (LCLs) the proportion of 
ITPR1-positive cells using immunofluorescence was significantly higher in mutant 
than control LCLs, consistent with an abnormality of nuclear calcium signaling 
feedback control. Super-resolution imaging supports the existence of an ITPR1-lined 
nucleoplasmic reticulum.  Mice with Itpr1 heterozygous null mutations showed no 
major iris defects.  Purkinje cells of the cerebellum appear to be the most sensitive to 
impaired ITPR1 function in humans.   Iris hypoplasia is likely to result from either 
complete loss of ITPR1 activity or structure-specific disruption of multimeric 
interactions.    
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Report 
Ida Mann in her classic 1925 paper on the development of the iris in human embryos 
and fetuses[1] describes four major morphological stages.  From 28-49 gestational days (GD) 
there is formation of the annular irido-hyaloid vessel at the distal rim of the optic cup, 
coincident with the apposition of the optic fissure and appearance of the lens placode.  
Between 50-77 GD, following the separation of the lens vesicle, the “mesodermal” iris 
appears as a thin layer distal to the lens, the central regions of which is known as the 
pupillary membrane.  This layer is contiguous with the peri-ocular mesenchyme and the 
mesenchyme surrounding the hyaloid vessels. From 78-84 GD the ectodermal iris appears as 
a separate outgrowth from the tip of the optic cup coinciding with the disappearance of the 
irido-hyaloid vessels. The final stage, from 85-175GD, involves growth of the ectodermal iris, 
the outer layer of which is contiguous with the future retinal pigment epithelium and the inner 
layer with the neural retina.  Both layers of the ectodermal iris eventually pigment.  The 
sphincter muscles appear to develop from cells of the distal outer layer supplied by radial 
vessels from the mesodermal iris.  The dilator musculature develops as a thin layer growing 
radially on the surface on the outer layer of the ectodermal iris. 
The best-studied malformation of the iris is complete aniridia (MIM 106210) [2] with 
more than 90% of cases caused by heterozygous loss-of-function (LOF) mutations in the 
paired- and homeo-domain containing transcription factor PAX6 (MIM 607108). PAX6-
associated aniridia is, however, a pan-ocular disease typified by foveal hypoplasia, cataracts 
and progressive corneal opacification in addition to the iris anomaly [3]. Extraocular disease is 
rare in PAX6-associated aniridia although structural brain anomalies and other sensory 
impairments have been identified [4]. Apparently isolated aniridia has also been reported in 
association with heterozygous LOF mutations in FOXC1 (MIM 601090) [5, 6] and PITX2 (MIM 
601542) [7] although these loci are more commonly associated with anterior segment 
dysgenesis (MIM 602482) [8]. Syndromic forms of aniridia have been described, the best 
known of which is WAGR (Wilms tumour, aniridia, genital malformations, intellectual disability 
(retardation); MIM 194072) resulting from a contiguous gene defect encompassing PAX6 and 
WT1 (MIM 607102) [9].  The other well-known syndromic form of aniridia is Gillespie 
syndrome (MIM 206700). Aniridia is, however, an incorrect description of iris malformation in 
Gillespie syndrome, which is a characteristic form of iris hypoplasia with “scalloping“ of the 
pupillary edge.  Gillespie syndrome typically presents as fixed dilated pupils in affected 
infants. Iridolenticular strands can be seen at regular intervals (Figure 1B) as can other 
remnants of the pupillary membrane. From the description of the embryology given above the 
iris defect in Gillespie syndrome would thus be consistent with a failure of development or 
maintenance of the sphincter musculature and the associated stroma.  The eye in Gillespie 
syndrome can be further distinguished from PAX6-related disease by the absence of foveal 
hypoplasia and corneal opacification. The key extra-ocular features of Gillespie syndrome are 
congenital hypotonia, non-progressive cerebellar hypoplasia and ataxia (Figure 1B-D) and 
variable, usually mild, neurocognitive impairment.  The inheritance of Gillespie syndrome has 
been considered heterogeneous with both autosomal dominant and autosomal recessive 
inheritance being postulated on the basis of convincing patterns in individual families [10, 11]. 
The clinical features of 13 affected individuals with a confident clinical diagnosis of Gillespie 
syndrome who were used in the molecular studies reported below are summarized in Table 1. 
We reviewed the available neuroimaging of each case, which showed that the cerebellar 
vermis atrophy is present early and is progressive particularly in the first five years of life 
(Figure 1B-D). The atrophy mainly affected the superior vermis progressing to involve the 
superior cerebellar hemispheres more than the inferior aspects.  Abnormal periventricular 
increased T2/FLAIR white matter signal was seen adjacent to the frontal horns on all 
examinations and older patients also had scattered foci of increased T2/FLAIR signal in the 
white matter, mainly frontally.   Until now the molecular basis of Gillespie syndrome was not 
known with causative mutations in PAX6, FOXC1 and PITX2 having been excluded in many 
reported cases [12]. 
Deciphering Developmental Disorders (DDD) is a UK and Ireland-wide project that aims to 
use whole exome sequencing to identify the cause of previously unexplained severe and 
extreme phenotypes which plausibly have their genesis in embryogenesis or early fetal brain 
development [13]. The study has UK Research Ethics Committee approval (10/H0305/83, 
granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland 
REC) with written consent being obtained from all participating families.  To date 13936 
probands have been recruited with DNA samples available in the majority from the affected 
individual and both parents (trios).  Three individuals have been recruited to DDD with a 
clinical diagnosis of Gillespie syndrome (261348, 263220, 272179; Figure 1A) and these were 
whole exome sequenced as part of the first 4294 trios. The technical and analytical details of 
the trio exome analysis used in DDD have been previously reported [14-16].  Briefly 
fragmented genomic DNA was the substrate for targeted pull-down using a custom Agilent 
SureSelect 55MB Exome Plus and 75-base paired-end sequenced on Illumina HiSeq. 
Alignment was performed using Burrows-Wheeler Aligner (BWA; version 0.59) and 
realignment around indels using GATK. Putative de novo mutations were identified from 
exome data using DeNovoGear software [17].   The functional consequence of each variant 
was assessed using the most severe consequence from Ensembl Variant Effect Predictor 
(VEP) [18]. Plausibly pathogenic mutations in known developmental disorders were identified 
by filtering by gene and allelic requirement using the DDG2P database combined with the 
minor allele frequencies as described [16].  Using this approach each of the Gillespie 
syndrome cases in DDD was found to carry a single plausible pathogenic variant, which was 
a de novo protein-altering mutation in ITPR1 (MIM 147265).   Two of these individuals 
(261348 & 263220) had different heterozygous mutations affecting the same reference base 
(261348 chr3 g.4856205G>C; 263220 chr3 g.4856205G>A hg19) which is predicted to result 
in an identical change in the open reading frame (p.Gly2539Arg).  The latter of these genomic 
mutations (3:4856205G>A) is recorded in 1/120716 (0.000008284) alleles in the ExAC 
database in an individual of recent African decent, although the inheritance or any associated 
phenotype of the carrier is not available.  Individual 272179 had a heterozygous in-frame 
deletion of a single codon (chr3 g.4856866-4856868delAAG; p.Lys2596del).  The BAM and 
VCF files from the first 4294 trios in the DDD project are available via the European Genome-
Phenome Archive (EGA).  All residue numbering uses reference sequence NP_001161744.1 
(Q14643-2; ENSP00000306253.8), which represents ITPR1 isoform 2 with a total of 2743 
amino acids and lacking a 15 amino acid insertion at Asp321.  The de novo status of each of 
these variants was confirmed using an independent sequencing technology (Sanger or 
Illumina MiSeq). On review of the exome data no other plausibly pathogenic variant could be 
identified on the second allele in each of the three DDD cases.  
Following identification of the de novo ITPR1 mutations in the DDD cases we reviewed whole 
exome sequences that had been independently generated on a previously reported [19, 20] 
mother (SVP) and daughter (SW) with Gillespie syndrome.  The exome capture had been 
performed using the SureSelectXT Human All Exon V5+UTRs kit (Agilent) followed by 150-
base paired-end sequencing on a NextSeq 500 (Illumina). The CLC Genomics Workbench 
version 7.5 (Aarhus, Denmark) was used for read mapping against GRCh37/hg19, followed 
by duplicate read removal and coverage analysis for all regions enriched with the SureSelect 
XT exome kit. Approximately 98% of the target regions were covered in both patients. A read 
depth of at least 10x was obtained for 80.26% and 90.75% of the SureSelect target regions in 
both affected individuals, respectively. Finally, quality-based variant calling and annotation 
was performed and the resulting variant lists were exported for filtering.   SVP and SW shared 
a single, heterozygous, ultra-rare missense mutation (not present in ExAC or 1000 genomes 
data) in ITPR1 (chr3 g.4821268A>G; p.Glu2094Gly) (Supplemental Data). This study was 
conducted following the tenets of Helsinki, and written informed consent was obtained from 
the participating family.  
Eight additional unrelated cases of Gillespie syndrome were identified via the eye 
malformation cohort held in the MRC Human Genetics Unit (MRC HGU) at the University of 
Edinburgh, a study approved by the UK Multiregional Ethics Committee (Reference: 
06/MRE00/76) with written informed consent obtained from the participating families.  Whole 
exome sequencing was available on one of these individuals (1388_1388) which, on review, 
was found to show a heterozygous mutation in ITPR1 identical to the chr3 g.4856866-
4856868delAAG;  p,Lys2596del allele mentioned above.  This mutation was subsequently 
shown to have occurred as a de novo mutation in this individual. No other plausible disease-
causing mutations were identified in ITPR1 from these exome analyses.  Targeted re-
sequencing was performed in the seven other individuals with a confident clinical diagnosis of 
Gillespie syndrome. Six exons of ITPR1 were selected - coding exons 46 and 52 to 56, which 
encode the region spanning Glu2094 and the entire calcium ion channel domain, respectively 
(Table S2). This revealed heterozygous mutations in all seven affected individuals; 4/7 
c.7615G>A p.Gly2539Arg, 2/7 c.7786_7788delAAG p.Lys2596del and 1/7 (chr3 
g.4821267G>C; p.Glu2094Gln) (Figure 1A).  In 6/7 of these individuals the mutation was not 
present in DNA from the mother and father (all clinically unaffected) and biological 
relationships were confirmed using highly informative genetic markers suggesting that the 
mutations had occurred de novo in the affected individual.  In 2018_2018 the mutation was 
not present in the unaffected mother but the father’s DNA sample was not available for 
analysis.  A separate cohort of 173 individuals with non-syndromic aniridia and with no 
mutation in PAX6 detected, were screened for mutations in ITPR1 using the targeted 
resequencing amplicons. No plausible disease-causing mutations were identified, suggesting 
that ITPR1 mutations are specific for iris hypoplasia associated with Gillespie syndrome and 
that this locus does not contribute to other forms of aniridia. Thus all thirteen affected 
individuals with a clinical diagnosis of Gillespie syndrome that were available to us for study 
were found to have ultra-rare protein altering mutations affecting only three residues in 
ITPR1, with at least ten of these mutations having occurred de novo.  
ITPR1 encodes a calcium-release channel that is inositol 1,4,5-trisphosphate (IP3)-
responsive. Heterozygous LOF mutations, mostly deletions encompassing ITPR1, have been 
identified in spinocerebellar ataxia type 15 (SCA15; MIM 606658).  SCA15 is characterized by 
very slowly progressive autosomal dominant cerebellar ataxia and cerebellar atrophy [21-26]. 
Haploinsufficiency for ITPR1 accounted for 2% of dominant ataxia in a screen of a large 
series of well-characterized families with the age of onset in the affected individuals with 
ITPR1 deletions in this series being between 18-66 years [23].  Earlier onset ITPR1-
associated cerebellar disease has been reported.  In two families with a congenital, non-
progressive spinocerebellar ataxia (SCA29; MIM 117360) the disease was found to co-
segregate with a different ultra-rare ITPR1 missense mutation in each family (encoding 
c.1759A>G; p.Asn587Asp and c.4639G>A; p.Val1547Met: These and all subsequent 
numbering converted to NP_001161744.1 (Q14643-2, ENSP00000306253.8) with 
pathogenicity scores for all variants provided in Table S3) [27]. Another multigeneration family 
with c,4639G>A; p.Val1547Met and a mild phenotype have been described [28].  More 
recently, de novo missense mutations have been found in infantile onset spinocerbellar ataxia 
(encoding c.800C>G; p.Thr267Arg, c. 800C>T; p.Thr267Met, c.830G>T; p.Ser277Ile, 
c.1736C>T; p.Thr579Ile) [29] and ataxic cerebral palsy (encoding c.1759A>G; p.Asn587Asp, 
c.4459_4460delinsGA; p.Ser1487Asp) [30]. In total, eight intragenic mutations, substituting 
seven residues, have been identified in 12 unrelated cases of cerebellar ataxia, with only one 
of these cases having an adult onset phenotype (Figure 2). It is notable that the more severe 
and earlier onset ITPR1-associated ataxia is caused predominantly by missense variants and 
that these missense variants are distinct from those associated with Gillespie syndrome. 
When trying to understand the molecular origins of the dominant phenotype, it is interesting to 
note that a dominant-negative effect has been described for mutations in several other 
transmembrane channel genes [31-33]. Thus we can hypothesize that a similar mechanism 
may account for the effects of the mutations identified here. Given that the ITPR1 protein 
forms a homotetramer (Fig. 2B), then only 1/16 assembled tetramers will contain four wildtype 
subunits, in the absence of any cotranslational assembly [34]. If a single mutated subunit can 
block channel function, then 94% of tetramers will be non-functional, thus potentially 
explaining the dominant phenotype. 
We were unaware of any methods for predicting whether protein-altering mutations 
are likely to show a dominant-negative effect and we speculated that such variants should 
generally be less structurally perturbing than other LOF pathogenic mutations, because a 
dominant-negative mechanism requires the complex to, at least, partially assemble. To 
address this, we predicted the structural destabilization [35] of pathogenic missense 
mutations with a known or likely dominant-negative mechanism from proteins that form 
transmembrane channels, and compared them to recessive mutations from the same proteins 
or dominant mutations from genes with no known dominant-negative effect (Figure S1). We 
observe a highly significant difference (p ≤ 0.0015) with the dominant-negative mutations 
inducing a lesser change in protein stability than the two other groups of mutations. 
Next, using the recently determined cryoelectron microscopy structure of the 
tetrameric ITPR1 protein [36], we predicted the effects of the missense mutations identified in 
this study, as well as the cerebellar ataxia-associated missense mutations mentioned above. 
All but one of the ITPR1 mutations are predicted to have mildly destabilising effects (Table 
S1).  We compared these mutations to a larger set of known dominant-negative mutations in 
transmembrane channels, recessive mutations in the same transmembrane channels, and 
other dominant mutations with no known dominant-negative association (Figure S1). We 
observe that the dominant-negative mutations are significantly less destabilising than the 
other groups. The pathogenic missense mutations in ITPR were found to be most similar to 
known dominant-negative mutations using these parameters. Only p.Gly2539Arg is predicted 
to be strongly destabilizing, although it is still within the range of some of the other known 
dominant-negative mutations. Additional evidence for the pathogenicity of p.Gly2539Arg 
comes from its position immediately N-terminal to the ion selectivity filter of the ITPR1 protein 
[37]. Indeed, site directed mutagenesis of p.Gly2539 to alanine has demonstrated a loss of 
channel activity in a number of in vitro assays [38].  Overall, this analysis strongly supports a 
dominant-negative mechanism for the mutations identified here, as has been observed in 
other transmembrane channels. 
We can also consider how the different ITPR1 mutations are located with respect to 
the three-dimensional structure of the complex (Fig. 2B). Interestingly, all three residues 
mutated in Gillespie syndrome are located near the centre of the channel, within or close to 
the transmembrane region, whereas all of the non-Gillespie mutations occur away from the 
centre within the cytoplasmic domains. Notably, 4/6 non-Gillespie positions are located at or 
near the IP3 binding site [36]. The only point mutation associated with adult-onset ITPR1-
associated ataxia (encoding p.Pro1068Leu) is located relatively near in space to another 
early-onset mutation, and is also predicted to be only mildly destabilizing, suggesting that it 
may also be associated with a dominant-negative mechanism, rather than the 
haploinsufficiency associated with SCA15 gene deletions. 
The dominant negative hypothesis requires the mutant protein to be translated, stable 
and correctly targeted.  To assess this we used lymphoblastoid cell lines (LCL) that had been 
established from five of the affected individuals with Gillespie syndrome.   Two of these 
individuals carried c.7615G>A p.Gly2539Arg (2021_2021, 2018_2018) and three had 
c.7786_7788delAAG p.Lys2596del (291_291, 2374_2374, 1388_1388). Western blot of 
protein extracted from unsynchronized cultures revealed a variable level of ITPR1 between 
control and mutant LCL with no obvious difference between the groups (data not shown).  
Protein localization was assessed using immunofluorescence staining with confocal 
microscopy or structured illumination microscopy (SIM).  As expected punctate perinuclear 
staining was seen in both control and mutant cell lines consistent with known localization to 
the smooth endoplasmic reticulum [39, 40](Figure 3A).  ITPR1 is also known to localize to 
structures within the nucleus known as the nucleoplasmic reticulum [41, 42].  In the Gillespie 
syndrome LCLs the most striking difference compared to control LCLs was a consistently 
higher proportion of cells that were positive ITPR1 using immunofluorescence (Figure 3B).  
Using quantitative analysis of super-resolution SIM images no significant differences could be 
detected in the number of fluorescence foci or the total volume of the ITPR1-positive regions 
within the whole cell or the nucleus (Figure 3C, S3). The irregularities in the nuclear outline in 
the mutant cells may be indicative of an increased number and/or increased size of the 
nucleoplasmic reticular pores (see Figure 4 in [42]).  These changes may reflect failure of a 
feedback loop caused by a deficit in calcium signaling within the nucleus.  However, we were 
unable to directly assess ITPR1-associated calcium signaling in the LCLs using ATP as no 
stimulation of calcium signaling was seen in either control or mutant cells (Figure S4). 
Heterozygous null, non-mosaic, 16.5 dpc mouse embryos and adult mice were 
created using CRISPR/Cas9 genome editing methodology (Supplementary Information).  
These embryos displayed no obvious morphological differences in the early development of 
the iris compared to their wild type littermates (Figure S2A).  Immunohistochemistry (IHC) of 
the wild type mouse embryos revealed no evidence of specific staining of ITPR1 in the 
developing iris (data not shown).  No change in expression of Pax6 could be detected 
between mutant and wild type embryos (Figure S2A).  Two heterozygous null adult mice 
could be examined at the age of 76 days with wild type littermate controls (Figure S2B). 
Although minor defects in the iris were noted in both mice no major anomalies that would be 
consistent with the phenotype seen in Gillespie Syndrome could be detected.  These data 
suggest that the role of ITPR1 in iris development is either indirect, acting at a later stage of 
development or is tolerant of 50% residual channel activity.  The latter explanation would be 
consistent with the lack of an iris phenotype in individuals affected with SCA15 in whom 
haploinsufficiency for ITPR1 is the predominant genetic mechanism. Of note, Ca2+ has been 
implicated in development of the eye in both chick and zebrafish, although the source of 
these ions has been thought to be extracellular (as reviewed in [43]). 
The data presented here provide strong evidence that Gillespie syndrome is a 
clinically- and neuroradiologically- distinct disorder that shows locus homogeneity.  The 
cerebellar anomalies in these cases are similar to that seen in the SCA29 phenotype.  We 
present evidence based on the predicted effect of mutations on the formation of multimeric 
channels that suggests that these mutations are likely to be acting by a dominant negative 
effect.  This protein structure based analysis is likely to have wide applicability in the 
interpretation of mutations, particularly in the important “channelopathy” class of human 
disease genes [44-46].  The iris hypoplasia, which typifies Gillespie syndrome, may be a 
consequence of lower level of residual function in ITPR1 (compared to SCA29) but, given that 
only specific residues are altered, it seems more likely that these mutations disrupt functional 
interactions that are critical to the formation and/or maintenance of the sphincter pupillae 
muscle. In this regard it is interesting that mutations in the gene encoding a smooth muscle 
actin (ACTA2, MIM 102620) have recently been reported with a very similar iris phenotype 
[47]. ITPR1 and ATCT2 may interact in smooth muscle as components of the cGMP kinase 
signaling complex [48]. 
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Note added in proof 
Gillespie syndrome Individual 1388_1388 described in this study is the same individual as 
F4:II2 who is described, with the same ITPR1 mutation, in the accompanying report by 
Gerber et al. Biallelic truncating and de novo missense ITPR1 mutations cause Gillespie 
syndrome. 
  
Figure Legends 
 
Figure 1: Human Genetic, Ophthalmic and radiological features of Gillespie 
syndrome 
A.  Diagrammatic representation of the Sanger sequencing chromatograms in 12 families in 
this study with a confident clinical diagnosis of Gillespie syndrome. In 9/12 de novo status of 
the mutations could be confirmed and in one family (SVP_SW) the mutation was inherited 
from an affected mother. B. Left panel: Image of the right eyes from 263220 and 5284_5284 
showing iris hypoplasia and iridolenticular strands (arrowed) typical of Gillespie syndrome. 
Middle panel: MR brain imaging of 261348 at the age of 1 year and 7 months showing minor 
prominence of the cerebellar folia of the vermis superiorly but by 4 years 8 months 
progressive cerebellar vermian volume loss and minor prominence of the superior cerebellar 
folia of both cerebellar hemispheres. Minor periventricular high T2/FLAIR signal adjacent to 
frontal and occipital horns (white arrowheads). Right panel. MR brain imaging of 5285_5285 
aged 11years 7months  showing moderate vermis and cerebellar hemisphere atrophy, more 
prominent superiorly and in the vermis with minor increased periventricular white matter T2 
signal adjacent to the frontal horns as well as a couple of foci within the frontal lobe white 
matter bilaterally(white arrowheads). C. Left panel: Right eye of 1388_1388 showing iris 
hypoplasia. Right panel: Individual 272179 at age 37 years.  MR brain showing moderate 
vermis and cerebellar atrophy, worse in the vermis and superiorly. Abnormal periventricular 
increased T2/FLAIR signal adjacent to the frontal horns (white arrowheads). D. A photo of the 
right eye of 91_91 at age 52 years (de novo c.6280G>C p.Glu2094Gln) showing iris 
hypoplasia with fixed mydriasis. The adjacent MR imaging shows mild cerebellar volume loss 
(cerebellar hemispheres and vermis), more so superiorly.  There is periventricular increased 
T2/FLAIR signal, most notably adjacent to the frontal horns with multiple foci of white matter 
increased T2/FLAIR signal elsewhere in the white matter mainly of the centrum semiovale.  
There is a minor degree of generalised cerebral atrophy. Gyral pattern appears normal. 
  
 Figure 2: De novo mutations affecting three residues in ITPR1 are the major 
cause of Gillespie syndrome 
A. Linear representation of ITPR1.  Amino acid numbering is based on NP_001161744.1 
(Q14643-2; ENSP00000306253.8) which has 2743 residues (encoded by the canonical 
transcript NM_001168272.1; ENST00000302640). The coloured boxes represent the 
following domains and features: green, ligand transferase domain; red, inositol 1,4,5 
triphosphate binding domain; yellow, 15 amino acid insertion in isoform Q14643-1 (which has 
2758 residues); brown RyR and IP3R homology domain; orange, intracellular transmembrane 
domain; blue, calcium ion transport channel. The heterozygous mutations associated with 
congenital cerebellar ataxia (blue text) mostly cluster towards the N-terminus at the ligand 
transferase and inositol 1,4,5 triphosphate binding domains, whereas those associated with 
autosomal dominant Gillespie syndrome (pink text) cluster towards the C-terminus at or near 
the intracellular transmembrane domain and calcium ion transport channel.  
B. Structure of the ITPR1 tetramer, left, and monomer, right (derived from PDB ID: 3JAV). 
The three mutation sites from this study associated with Gillespie syndrome shown in red, 
and six sites previously associated with other disorders shown in blue.  
 Figure 3: Functional characterization of ITPR1/Itpr1 mutations 
Confocal imaging of lymphoblastoid cell lines (LCL) showing representative examples from 
unaffected individuals (control 1 as an exemplar) or individuals with Gillespie syndrome 
(291_291 and 2018_2018 as exemplars). The top panel shows DAPI stained nuclei. The 
panel below shows the punctate staining in the nuclear and perinuclear regions on 
immunofluorescence staining using an anti-ITPR1 antibody.  ITPR1 mutant cells consistently 
showed more punctate staining within the nucleus compared to the controls. The third panel 
shows the merge of the first and second.  The fourth panel shows super-resolution SIM 
imaging of representative LCL nuclei from each of the genotypes, B. The number of ITPR1-
stain positive cells in LCLs with or without mutations in ITPR1 were analysed using ImageJ. 
Area, shape descriptor and mean gray value were measured for each cell. In control LCLs 
<20% of the DAPI positive (+ve) cells were also +ve for ITPR1 immunofluorescence.  In cells 
carrying either of the indicated mutations, 30-50% of the cells were ITPR1 positive.  Chi 
squared tests of the difference between the mutant and control cells suggest these are very 
unlikely to be chance observations. C. Quantitative fluorescence analysis from 3D super-
resolution images showing the mean total volume of ITPR1-positive foci for the following 
compartments within the cell: whole cell, reticular component, whole nucleus and low-DAPI 
regions of the nucleus. Multiple individual cells from two independent patient-derived LCLs 
per genotype were obtained using Structured Illumination Microscopy (SIM).  The masking 
strategy used to obtain these data is outlined in Figure S3.  No significant difference was 
observed between genotypes. 
 
 
 
Table 1:  Summary of the clinical and molecular finding in individuals with Gillespie syndrome 
Residue Involved  Glu2094 Gly2539 Lys2596 
Patient ID 91_91 SVP SW 261348 263220 2021_2021 2018_2018 5284_5284 5285_5285 272179 291_291 2374_2374 1388_1388 
Genomic mutation 
hg19 
chr3 
g.4821267G>C 
chr3 
g.4821268A>G 
chr3 
g.4856205G>C 
chr3 
g.4856205G>A 
chr3 
g.4856205G>A 
chr3 
g.4856205G>A 
chr3 
g.4856205G>A 
chr3 
g.4856205G>A 
chr3 g.4856866-
4856868delAAG 
chr3 g.4856866-
4856868delAAG 
chr3 g.4856866-
4856868delAAG 
chr3 g.4856866-
4856868delAAG 
Genotype Het Het Het Het Het Het Het Het Het Het Het Het 
Mutation Type missense_variant missense_variant missense_variant missense_variant missense_variant missense_variant missense_variant missense_variant inframe_deletion inframe_deletion inframe_deletion inframe_deletion 
NM_001168272.1;  
ENST00000302640 c.6280G>C c.6281A>G c.7615G>C c.7615G>A c.7615G>A c.7615G>A c.7615G>A c.7615G>A c.7786_7788delAAG c.7786_7788delAAG c.7786_7788delAAG c.7786_7788delAAG 
NP_001161744.1;  
ENSP00000306253.8 
consequence 
p.(Glu2094Gln) p.(Glu2094Gly) p.(Gly2539Arg) p.(Gly2539Arg) p.(Gly2539Arg) p.(Gly2539Arg) p.(Gly2539Arg) p.(Gly2539Arg) p.(Lys2596del) p.(Lys2596del) p.(Lys2596del) p.(Lys2596del) 
De novo mutation Yes NK Mat Yes Yes Yes NK Yes Yes Yes Yes Yes Yes 
Sex Female Female Female Male Female Female Female Female Male Male Female Female Female 
Prenatal Growth                           
Gestation NK NK NK 40 40 40 NK 40 NK 37 40 40 37  
Birth weight (SD) NK NK "Normal" 0.76 1.09 0.99 NK -1.17  NK 1.25 -1.17 -0.75  0.04 
Postnatal Growth                           
Age (yearr) 55 34 13 7.19 14.62 28 NK 3.4 12 36.95 10 16  19.75 
Height_SD 0.53  NK NK -0.38 NK NK NK -3.12  NK NK -3 -4.2  1 
Weight_SD -2.31  NK NK 0.19 NK NK  NK  -1.7  NK NK -2  NK  1.8 
OFC_SD 0.35  NK NK -0.89 60.7 NK  NK  -0.58  NK 2.39  NK  NK  2 
Neurology and 
development                           
Sat independently Late NK NK 2 years 2-2.5 years 13 months NK  9 months  NK Late 18 months 3 years  30 months 
Walked independently 8-9 years NK NK 10 years  Not yet achieved >6 years  NK Not yet achieved  NK 10 years Not yet achieved.  >10 years  7 years 
Speech delay Yes NK NK Severe Yes Moderate  NK  NK  NK Moderate-severe Yes Yes  Yes 
Intellectual disability Mild to moderate Learning difficulties Mild 
Learning 
difficulties Mild Mild to moderate NK Mild Moderate Mild-moderate Global delay Global delay Mild 
Hypotonia NK  NK Yes No Yes Yes  NK Yes Yes Yes Yes Yes Yes, severe 
Ataxia Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes, severe 
Cerebellar 
hypoplasia/atrophy Yes Yes Yes Yes Yes Yes NK Yes Yes Yes Yes Yes Yes 
Ophthalmology                           
Bilateral Iris 
hypoplasia Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Foveal hypoplasia No NK NK NK Yes  NK  NK  NK  NK No NK No  No 
Visual impairment Mild NK  NK NK Mild  NK  NK Mild NK  NK Mild Moderate NK 
Negative PAX6 screen Yes Exome Exome Yes Yes Yes Yes No No Yes Yes Yes Yes 
Clinical Diagnosis of 
Gillespie syndrome Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Other Features                           
Other Clinical 
Features 
Gastrooesophageal 
reflux, depression None  None Gastroesophageal reflux Scoliosis, gall stones None None Patent foramen ovale and a mild pulmonary valve 
stenosis 
None 
Scoliosis, 
macrocephaly, small 
ears 
None Frontal bossing slight facial dysmorphism 
 NK: not known. Het: heterozygous variant.  SD: Standard Deviation. OFC: occipito-frontal circumference 
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